Literature DB >> 29805660

Association between 5-lipoxygenase expression, and malignant behaviors and poor prognosis in esophageal squamous cell carcinoma.

Chun-Ying Bai1,2, Jun-Yi Zhang1,3, Tie-Wei Shi2, Yu-Qin Bai3, Bing-Li Wu1,4, Ze-Peng Du5, Zhi-Yong Wu1,6, Xiu-E Xu1,7, Shao-Hong Wang5, Jian-Yi Wu1,5, Rui-Yun Te2, Jing-Yi Zhang3, Li-Yan Xu1,7, En-Min Li1,4.   

Abstract

5-lipoxygenase (5-LO) catalyzes the first step of arachidonic acid metabolism to inflammatory mediator leukotrienes. The present study assessed 5-LO expression in esophageal squamous cell carcinoma (ESCC) tissue specimens for associations with clinicopathological and survival data from patients, then explored 5-LO activity in ESCC cells in vitro. 5-LO expression was detected in tissue microarrays containing 297 ESCC samples using immunohistochemistry. Kaplan-Meier curves were used to analyze the survival significance of 5-LO expression and relative risk was evaluated using the multivariate Cox proportional hazards model. Cultured tumor cells were subjected to gene transfection, western blotting, and cell migration and proliferation assays. 5-LO protein was primarily expressed in normal cell cytoplasm and/or membrane, and never in the whole cytoplasm, whereas 5-LO was expressed diffusely in ESCC tissues with nearly homogeneous whole-cytoplasm staining. 5-LO expression was significantly associated with tumor regional lymph node metastasis (P=0.013) and pTNM stage (P=0.004). 5-LO expression was associated with poor overall survival (P=0.029). Multivariate analysis demonstrated that 5-LO overexpression was an independent prognostic factor for ESCC patients (P=0.041). Furthermore, the inhibition of 5-LO expression reduced ESCC cell viability and migration in vitro. These data provide further evidence that the upregulation of 5-LO expression is associated with advanced stages of disease and poor ESCC prognosis, and that 5-LO expression may independently predict overall survival in patients with ESCC. The inhibition of 5-LO expression reduced ESCC malignant behavior in vitro.

Entities:  

Keywords:  5-lipoxygenase; biomarker; esophageal squamous cell carcinoma; prognosis; tumor cell malignant behavior

Year:  2018        PMID: 29805660      PMCID: PMC5958678          DOI: 10.3892/ol.2018.8527

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.

Authors:  Wen G Jiang; Anthony G Douglas-Jones; Robert E Mansel
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-12-20       Impact factor: 4.006

2.  5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor.

Authors:  M Romano; A Catalano; M Nutini; E D'Urbano; C Crescenzi; J Claria; R Libner; G Davi; A Procopio
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

3.  A mechanistic study of colon cancer growth promoted by cigarette smoke extract.

Authors:  Yi N Ye; William K K Wu; Vivian Y Shin; Chi H Cho
Journal:  Eur J Pharmacol       Date:  2005-09-05       Impact factor: 4.432

4.  Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: the possible role of nuclear factor kappaB signaling pathway.

Authors:  Hui Yang; Xudong Jia; Xiaoxin Chen; Chung S Yang; Ning Li
Journal:  Int J Cancer       Date:  2012-03-02       Impact factor: 7.396

5.  Cancer statistics: updated cancer burden in China.

Authors:  Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

6.  Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma.

Authors:  Philip C Boger; James D Shutt; James R Neale; Susan J Wilson; Adrian C Bateman; John W Holloway; Praful Patel; Anthony P Sampson
Journal:  Histopathology       Date:  2012-06-13       Impact factor: 5.087

7.  Cardioprotective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion.

Authors:  Oleksandr O Lisovyy; Victor E Dosenko; Vasyl S Nagibin; Lesya V Tumanovska; Maria O Korol; Olga V Surova; Olexiy O Moibenko
Journal:  Acta Biochim Pol       Date:  2009-12-11       Impact factor: 2.149

8.  The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma.

Authors:  Huiying Zhi; Jian Zhang; Gengxi Hu; Jiayun Lu; Xiuqin Wang; Chuannong Zhou; Min Wu; Zhihua Liu
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

9.  Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China.

Authors:  Gina D Tran; Xiu-Di Sun; Christian C Abnet; Jin-Hu Fan; Sanford M Dawsey; Zhi-Wei Dong; Steven D Mark; You-Lin Qiao; Philip R Taylor
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

10.  Increased expression of 5-lipoxygenase in high-grade astrocytomas.

Authors:  Narendra Nathoo; Richard A Prayson; Judy Bondar; Linda Vargo; Susana Arrigain; Edward J Mascha; John H Suh; Gene H Barnett; Mladen Golubic
Journal:  Neurosurgery       Date:  2006-02       Impact factor: 4.654

View more
  3 in total

1.  Knock-out of 5-lipoxygenase in overexpressing tumor cells-consequences on gene expression and cellular function.

Authors:  Hannah Weisser; Tamara Göbel; G Melissa Krishnathas; Marius Kreiß; Carlo Angioni; Duran Sürün; Dominique Thomas; Tobias Schmid; Ann-Kathrin Häfner; Astrid S Kahnt
Journal:  Cancer Gene Ther       Date:  2022-09-16       Impact factor: 5.854

2.  Paeonol prevents migration and invasion, and promotes apoptosis of cervical cancer cells by inhibiting 5‑lipoxygenase.

Authors:  Shao-Qin Sheng; Lei-Yuan Yu; Xian-Wei Zhou; Hong-Yi Pan; Feng-Ying Hu; Jia-Li Liu
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

Review 3.  The role of ferroptosis in esophageal cancer.

Authors:  Zimin Wang; Sikai Wu; Chengchu Zhu; Jianfei Shen
Journal:  Cancer Cell Int       Date:  2022-08-23       Impact factor: 6.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.